Condition
Macular Telangiectasia Type 2
Total Trials
5
Recruiting
0
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
5Total
P 2 (3)
P 3 (2)
Trial Status
Completed3
Active Not Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06397131Phase 3Active Not RecruitingPrimary
A Study to Determine the Safety and Efficacy of NT-501 With MHFM
NCT04729972Phase 2CompletedPrimary
Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2
NCT03319849Phase 3CompletedPrimary
A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
NCT04907084Phase 2Active Not RecruitingPrimary
Serine and Fenofibrate Study in Patients With MacTel Type 2
NCT01949324Phase 2CompletedPrimary
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
Showing all 5 trials